<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2905257491
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FENTEX 50MG/ML SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PHENYTOIN SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        128.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AB02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Phenytoin belongs to a group of drugs known as hydantoins. It is called an anticonvulsant because it works by controlling the overactivity in the brain that can cause epilepsy or seizures (fits).<br />Fentex is used to:<br />&bull; control epileptic fitts involving jerking and spasm of the muscles (known as grand mal fits)<br />&bull; prevent and treat fits resulting from brain surgery or head injury.<br />You should consult your doctor if you are unsure why you have been given Fentex if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use FENTEX&reg;:</strong><br />&bull; if you are allergic to phenytoin or any of the other ingredients of this medicine (listed in section 6) or to any other hydantoin drug (such as ethotoin or methoin)<br />&bull; if you have a slow heart beat or heart problems that interfere with the rate at which your heart beats<br />&bull; if you are allergic to other medicines for epilepsy<br />&bull; if you are also taking delavirdine (used for HIV therapy)<br />&bull; if you suffer from certain conditions that affect the heart rhythm for example a decreased heart rate (sinusbradycardia), heart block (sinoatrial block or A-V block) or Adams-Stokes syndrome.</p><p><br />Make sure your doctor knows if you suffer from any of the above before you are given the injection.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or nurse before you are given <strong>FENTEX&reg;</strong> if you suffer from or have suffered in the past from any of the following conditions:<br />&bull; low blood pressure or heart failure<br />&bull; disease of the liver or kidneys<br />&bull; diabetes<br />&bull; porphyria (an inherited condition affecting the nervous system and skin, characterised by abdominal pain, vomiting or muscle weakness)<br />&bull; if you have drunk a large amount of alcohol recently or if you drink large amounts of alcohol regularly or if you have alcohol dependence<br />&bull; potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of Phenytoin sodium, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially lifethreatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment<br />&bull; if you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Phenytoin sodium, you must not be re-started on Phenytoin sodium at any time<br />&bull; heart rhythm problems<br />&bull; if you develop a rash or these skin symptoms, stop taking FENTEX&reg;, seek immediate advice from a doctor and tell that you are taking this medicine.</p><p>Consult your doctor before discontinuing FENTEX&reg;. If you suddenly stop using this medicine you may have a seizure.</p><p><br />The risk of these serious skin side effects may be associated with a variant in genes in a subject with Chinese or Thai origin. If you are of such origin and have been tested previously carrying this genetic variant (HLA-B*1502), discuss this with your doctor before using FENTEX&reg;.</p><p><br />Black patients may be at greater risk of liver problems, serious skin reactions and allergic reactions. If you are taking phenytoin at the same time as you receive radiation therapy to your head and the dose of another medication called corticosteroids is reduced, you may more likely to develop a severe skin rash called erythema multiform or one that causes blistering called Stevens Johnson Syndrome or Toxic Epidermal Necrosis (see Possible Side Effects in section 4).</p><p><br />A small number of people being treated with anti-epileptics such as Phenytoin have had thoughts of harming or killing themselves, if at any time you have these thoughts, immediately contact your doctor. Tell your doctor if any of these apply to you as special care may be needed. Your doctor will take particular care with this medicine if you are elderly or gravely ill.</p><p><br />Phenytoin may precipitate or aggravate absence seizures and myoclonic seizures (two specific types of epilepsy).</p><p><strong>Other medicines and FENTEX&reg;</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.<br />This will allow your doctor to decide whether it is safe for you to be given phenytoin.</p><p><br />Some medicines can affect the way FENTEX&reg; works or Fentex itself can reduce the effectiveness of other medicines taken at the same time. These include:<br />&bull; medicines used for epilepsy or fits (e.g. carbamazepine, lamotrigine, phenobarbital, sodium valproate and valproic acid, topiramate, oxcarbazepine, succinimides including ethosuximide and vigabatrin)<br />&bull; corticosteroids e.g. prednisolone (used in numerous situations to aid the body&rsquo;s healing process)<br />&bull; medicines used to treat fungal infections (e.g. amphotericin B, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole and miconazole)<br />&bull; medicines used to treat skin diseases (e.g. methoxsalen)<br />&bull; medicines used for tuberculosis and other infections (e.g. chloramphenicol, isoniazid, rifampicin, sulphonamides, sulfadiazine, sulfamethizole, sulfamethoxazole-trimethoprim, sulfaphenazole, sulfasoxazole, doxycycline and ciprofloxacin)<br />&bull; medicines used for asthma and bronchitis ( e.g. theophylline)<br />&bull; medicines used for diabetes (e.g. tolbutamide)<br />&bull; medicines used for high blood pressure (e.g. calcium channel blockers like diltiazem, felodipine)<br />&bull; medicines used for pain and inammation (e.g. phenylbutazone, salicylates, including aspirin and steroids)<br />&bull; medicines used for stomach ulcers and heartburn (e.g. omeprazole, sucralfate, the medicines known as H2 antagonists e.g. cimetidine, ranitidine, famotidine and some antacids)<br />&bull; medicines used for sleeplessness, depression and psychiatric disorders (e.g. chlordiazepoxide, clozapine, diazepam, disulram, lithium, methadone, fluoxetine, fluvoxamine, sertraline, haloperidol, levodopa, paroxetine, methylphenidate, phenothiazines, quetiapine, trazodone, reserpine, tricyclic<br />antidepressants and viloxazine)<br />&bull; medicines used for cancer (e.g. antineoplastic agents like teniposide, uorouracil, capecitabine, bleomycin, carboplatin, cisplatin, doxorubicin and methotrexate)<br />&bull; medicines used for organ and tissue transplants, to prevent rejection (e.g.ciclosporin, tacrolimus)<br />&bull; medicines used for heart and circulation problems (e.g. dicoumarol, amiodarone,digitoxin, digoxin, nisoldipine, disopyramide, mexiletine, furosemide and quinidine , reserpine, warfarin and calcium channel blockers including diltiazem and nifedipine)<br />&bull; hormone replacement therapies (oestrogens) and oral contraceptives (the birth control pill)<br />&bull; medicines used to lower high blood cholesterol and triglycerides (e.g. atorvastatin, fluvastatin, simvastatin)<br />&bull; medicines used in the treatment of HIV infection (e.g. delavirdine, efavirenz, fosamprenavir, indinavir, lopinavir, nelnavir, ritonavir, saquinavir)<br />&bull; medicines used to expel parasitic worms from the body (e.g. albendazole, praziquantel)<br />&bull; medicines used to treat thyroid disorders (e.g. thyroxine)<br />&bull; some medicines used in operations, e.g. halothane, methadone (an anaesthetic) and neuromuscular blockers (used to relax muscles e.g. pancuronium, vecuronium, rocuronium and cisatracurium)<br />&bull; some products available without a prescription (e.g. folic acid, vitamin D) Blood test may be necessary every six months to monitor the amount of folic acid in the blood<br />&bull; the herbal remedy St. John&rsquo;s wort (Hypericum perforatum) should not be taken at the same time as this medicine. If you have already taken St. John&rsquo;s wort, consult your doctor before stopping St. John&rsquo;s wort preparations<br />&bull; anticoagulants, e.g. warfarin (as its effect may be enhanced by phenytoin)<br /><strong>&bull; FENTEX&reg; may also interfere with certain laboratory tests that you may be given.</strong></p><p><strong>FENTEX&reg; with food, drink and alcohol</strong><br />Speak to your doctor before being given this medicine if you have recently had a drink of alcohol. Drinking a lot of<br />alcohol can also aect the concentration of Phenytoin in your blood.</p><p><br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<br />If you do get pregnant while you are taking FENTEX&reg;, you must tell your doctor straight away. It is important that your epilepsy remains well controlled, but, as with other anti-epilepsy treatments, there is a risk of harm to the foetus.<br />Make sure you are very clear about the risks and benefits of taking FENTEX&reg;.<br />Do not stop taking Fentex until you have seen your doctor as it is important to control your fits. If given during pregnancy phenytoin may affect the baby but your doctor may decide that it is very important that you continue with phenytoin. He or she will explain the risks to you.<br />As phenytoin is released into breast milk, you should not breast-feed if you are being given this medicine.</p><p><strong>Driving and using machines</strong><br />FENTEX&reg; may cause dizziness or drowsiness. If you experience these symptoms, do not drive or use any tools or<br />machinery.<br />Ask your doctor for advice before taking any medicine.</p><p><br /><strong>FENTEX&reg; contains ethanol and sodium</strong><br />This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially &lsquo;sodium- free&rsquo;. This medicinal product contains 10 % vol ethanol (alcohol), i.e. up to 395.75 mg per dose, equivalent to 7.9ml beer, 3.2ml wine per dose.</p><p>Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FENTEX&reg; is given by a doctor or nurse. It may be given as an injection slowly into a muscle or a large vein. Alternatively, it may be diluted and given as a drip or infusion into one of your large veins (intravenously). When given as an intravenous infusion, FENTEX&reg; must be diluted with normal saline. Intramuscular or intravenous Fentex should not be added to dextrose or dextrose-containing solutions as this could interfere with the dose of this medicine.<br />The correct dose will be calculated by your doctor according to your body weight and will be written as the equivalent&nbsp;dose of phenytoin sodium (PE). The dose will be as mg per dose if given as an injection or mg per ml of solution if given as an infusion (drip). A repeat injection may be given after 30 minutes if necessary.<br />During your treatment your doctor may monitor your blood levels of phenytoin by taking regular blood samples.<br />Sometimes it is necessary to give FENTEX&reg; into your muscle if you cannot continue to take it by mouth. This is not normally continued for longer than one week. When switching from oral Phenytoin to intramuscular injection, the dose needs to be increased by approximately 50%. When switching back to oral Phenytoin, the dose should be reduced to half the original oral dose for the same period of time that the intramuscular injection was given. This is because phenytoin continues to be released from your muscles for some time after the injections have been given.</p><p><strong>The recommended dose is as follows:<br />Adults</strong><br />Severe epileptic seizure or fits (Status Epilepticus)<br />A dose of 10 to 15 mg per kg of body weight is given intravenously at a rate not exceeding 50 mg per minute in adults.<br />This is followed by more FENTEX&reg; given every 6 to 8 hours either by injection or by mouth.<br />If FENTEX&reg; does not stop your seizures, other treatments will be tried.</p><p>Cardiac arrhythmias (variations to normal heartbeat)<br />A dose of 3.5 to 5 mg per kg of body weight is given intravenously, at a rate not exceeding 50 mg per minute. This may be repeated a second time.</p><p>Neurosurgery<br />A dose of 100 to 200 mg may be given into your muscle (intramuscularly) approximately every 4 hours during surgery and for two to three days afterwards to prevent seizures. This dosage may then be reduced to a maintenance dose of 300 mg daily and adjusted according to your blood levels.</p><p><strong>Elderly</strong><br />Lower or less frequent dosing may be needed in some elderly patients due to decreased clearance of FENTEX&reg; . Your doctor may not need to change your dose, but side effects can occur more often in the elderly.</p><p><strong>Kidney or liver problems</strong><br />Make sure your doctor knows if you have liver or kidney problems as you may need your dose adjusted.<br />&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>&nbsp;No dosage adjustment is required, but children tend to breakdown the medicine faster than adults and this may mean that your doctor has to change the number or timing of the Fentex doses.</p><p><strong>Use in neonates (Very young babies)</strong><br />The starting dose is usually 15 to 20 mg per kg of baby weight. Intravenous FENTEX&reg; should not be given to neonates at a rate faster than 1 to 3 mg per kg body weight per minute. Intravenous FENTEX&reg; is more reliably absorbed than oral Phenytoin in very young babies.</p><p>If you think you have been given more FENTEX&reg; than you should have Tell your doctor immediately.<br />FENTEX&reg; is dangerous in overdose.</p><p>The initial signs are nystagmus (condition of involuntary eye movement), diplopia (double vision), ataxia (the loss of full control of bodily movements) and dysarthria (motor speech disorder).</p><p>Other signs are tremor, hyperexia (muscle spasms), lethargy, nausea, vomiting. The patient may become comatose and hypotensive. Death is due to respiratory and circulatory depression.</p><p><strong>If you think you have missed a dose of FENTEX&reg;</strong><br />If you think that you may have missed a dose, tell your doctor immediately.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side-effects, although not everybody gets them.<br /><strong>Important: If you experience any of the following serious side effects contact your doctor</strong> <strong><u>immediately</u></strong>.<br />&bull; sudden wheeziness, diffculty in breathing, swelling of eyelids, face or lips, rash or itching (especially affecting the whole body). There is a higher incidence of this in black patients<br />&bull; if you experience skin discolouration, swelling and pain where the injection was given which then starts to spread down your arm to your hands and fingers. This may mean you have a condition known as Purple Glove Syndrome. In most cases this will improve on its own but in some cases it<br />can be serious and require urgent medical treatment<br />&bull; if you develop potentially life-threatening skin rashes that causes blistering (this can affect the mouth and tongue). These may be signs of a condition known as Stevens Johnson Syndrome or toxic epidermal necrolysis (TEN). These have been reported very rarely<br />&bull; if you notice bruising, fever, you are looking pale or you have a severe sore throat. These may be the first signs of an abnormality of the blood, including decrease in the number of red blood cells, white cells or platelets. Your doctor may take regular blood samples to test for these effects.<br />&bull; skin rash, fever, swollen glands, increase in a type of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs, heart, kidneys and large intestine), you may also experience pain and inflammation of the joints, these may be signs of a hypersensitivity reaction (e.g. drug reaction or rash with Eosinophilia and Systemic Symptoms (DRESS) or be related to a condition called systemic lupus erythematosus (SLE)<br />&bull; if you experience confusion or have a severe mental illness, as this may be a sign that you have high amounts of phenytoin in your blood. On rare occasions, when the amount of the phenytoin in the blood remains high, irreversible brain injury has occurred. Your doctor may test your blood to see how much phenytoin is in the blood and may change your dose.</p><p>Other side effects that may occur are as below:<br />Not known: frequency cannot be estimated from the available data<br />&bull; <strong>effects on your nervous system:</strong> unusual eye movements, unsteadiness, difficulty in controlling movements, shaking, abnormal or uncoordinated movements, slurred speech, confusion, pins and needles or numbness, drowsiness, dizziness, vertigo, sleeplessness, nervousness, twitching muscles, headaches and change in taste<br />&bull; <strong>effects on your skin: </strong>skin rash including measles-like rash which is usually mild<br />&bull; <strong>effects on your stomach and intestines:</strong> feeling sick, being sick and constipation<br />&bull; <strong>effects on your blood and lymph system:</strong> swelling of the lymph glands<br />&bull; <strong>effects on your liver and kidney: </strong>inflammation of the kidneys and liver, liver damage or liver failure which can lead to death (seen as yellowing of the skin and whites of the eye), abnormal liver function<br />&bull; <strong>effects on your reproductive system and breasts:</strong> changes in the shape of the penis, painful erection<br />&bull; <strong>effects on your hands, face and body: </strong>changes in the hands with difficulty in straightening the fingers, changes in facial features, enlarged lips or gums, increased or abnormal body or facial hair &bull; effects on medical tests: abnormal thyroid function tests<br />&bull; <strong>effects on your respiratory system: </strong>problems breathing including complete stopping of breathing, inflammation of the lining of the lung<br />&bull;<strong> effects on your immune system:</strong> problems with the body&rsquo;s defense against infection, inflammation of the wall of the arteries<br /><strong>&bull; effect on your heart and circulation:</strong> low blood pressure, enlargement of blood vessels. Your blood pressure may also be lowered and experience heart rhythm problems when Fentex is injected into your vein too quickly<br /><strong>&bull; effects on your bones:</strong> there have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor if you are on long-term antiepileptic medication, have a history of osteoporosis or take steroids<br /><strong>&bull; effects on injection site:</strong> Intramuscular phenytoin administration may cause pain, tenderness, dying or sloughing of skin cells and formation of an infection at the injection site.</p><p><strong>Please see your doctor if</strong> you notice any of these side effects and they cause you concern or if you notice any side<br />effects not listed in this leaflet.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />This medicine should not be used after the expiry date which is stated on the ampoule (a small bottle) label and carton, after EXP. The expiry date refers to the last day of that month.<br />The ampoules should be protected from light and stored at a temperature not greater than 30&deg;C.<br />If only part of the contents of an ampoule is used, the remaining solution should be discarded.<br />Solutions in which a haziness or precipitate develops should not be used.<br />The solution should not be mixed with any other drugs.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is phenytoin sodium. Each 1ml of this solution contains 50mg of phenytoin sodium.<br />The other ingredients are propylene glycol, ethyl alcohol and sodium hydroxide and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FENTEX® is a clear, colorless, particle-free solution. Each carton contains ten 5ml ampoules of FENTEX® .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi</p><p>Riyadh-kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2020
SPM190280  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">ينتمي فينيتوين إلى مجموعة من الأدوية تعرف باسم هيدانتوينس. يطلق عليها مضادات النوبات لأنها تعمل عن طريق التحكم في النشاط الزائد في الدماغ الذي يمكن أن يسبب النوبات أو الصرع (نوبة)</p><p style="direction: rtl;"><strong>:يستعمل فنتكس في الحالات التالية</strong></p><p style="direction: rtl;">&nbsp; للسيطرة على نوبات الصرع التي تشمل الرجيج وتشنج العضلات (المعروفة باسم نوبات الصرع الكبيرة)-</p><p style="direction: rtl;">&nbsp; لمنع وعلاج النوبات الناتجة عن جراحة الدماغ أو إصابة الرأس-</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يجب عليك استشارة طبيبك إذا كنت غير متأكد من سبب إعطائك محلول فنتكس أو إذا لم تشعر بتحسن أو إذا كنت تشعر بأن حالتك هي أسوأ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>:لا تستخدم محلول فنتكس إذا كنت</strong></p><p style="direction: rtl;">&nbsp;إذا كنت تعاني من حساسية تجاه فينيتوين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6) أو أي دواء هيدانتوين آخر (مثل: إيثوتوين أو ميثوتين)-</p><p style="direction: rtl;">&nbsp;إذا كنت تعاني من نبضات قلب بطيئة أو مشاكل في القلب التي تتداخل مع معدل ضربات قلبك-</p><p style="direction: rtl;">&nbsp; إذا كنت تعاني من حساسية لأدوية أخرى خاصة بعلاج الصرع-</p><p style="direction: rtl;">&nbsp;إذا كنت تتناول ديلافيردين أيضاً (دواء يستعمل لعلاج فيروس نقص المناعة البشرية)-</p><p style="direction: rtl;">إذا كنت تعاني من بعض الحالات التي تؤثر على نبضات القلب على سبيل المثال انخفاض معدل ضربات القلب (بطء القلب ألجيبي)، انحصار القلب (الانحصار الجيبي الأذيني أو الانحصار الأذيني البطيني) أو متلازمة آدامز ستوكس</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تأكد من أن طبيبك يعرف ما إذا كنت تعاني من أي من الحالات المذكورة سابقاً قبل إعطاءك الحقنة</p><p style="direction: rtl;"><strong>:التحذيرات</strong></p><p style="direction: rtl;">تحدث إلى طبيبك أو الممرضة قبل أن يتم اعطاءك محلول فنتكس إذا كنت تعاني أو عانيت في الماضي من أي من الحالات التالية</p><p style="direction: rtl;">انخفاض ضغط الدم أو قصور القلب-</p><p style="direction: rtl;">مرض في الكبد أو الكليتين-</p><p style="direction: rtl;">داء السكري-</p><p style="direction: rtl;">البورفيريا (وهي حالة وراثية تؤثر على الجهاز العصبي والجلد، وتتميز بألم في البطن أو القيء أو ضعف العضلات)-</p><p style="direction: rtl;">إذا كنت قد شربت كمية كبيرة من الكحول مؤخراً أو إذا كنت تشرب كميات كبيرة من الكحول بانتظام أو إذا كان لديك إدمان كحولي-</p><p style="direction: rtl;">إذا تم الإبلاغ عن طفح جلدي محتمل يهدد الحياة (متلازمة ستيفنز جونسون، انحلال البشرة السمي) باستعمال الفينيتوين الصوديوم التي تظهر في بادئ الأمر&nbsp;كبقع&nbsp;تشبه بقع حمراء&nbsp;أو بقع دائرية غالباً مع بثور مركزية على الجذع. وتشمل علامات إضافية للبحث عنها القرحة في الفم والحنجرة والأنف والأعضاء التناسلية والتهاب الملتحمة (عيون حمراء ومنتفخة). وغالباً ما تصاحب هذا الطفح الجلدي المهدد للحياة ظهور أعراض تشبه أعراض الانفلونزا. وقد يتطور الطفح الجلدي إلى تقرحات أو تقشير الجلد على نطاق واسع. فترة الخطر الأعلى عند حدوث هذه التفاعلات الجلدية هي في غضون الأسابيع الأولى من العلاج.</p><p style="direction: rtl;">إذا تطورت لديك متلازمة ستيفنز &ndash; جونسون أو انحلال البشرة السمي مع استعمال فينيتوين صوديوم، فيجب عليك عدم إعادة تناول جرعات فينيتوين صوديوم في أي وقت</p><p style="direction: rtl;">مشاكل في ضربات القلب-</p><p style="direction: rtl;">&middot;&nbsp; إذا كنت تعاني من طفح جلدي أو ظهور أعراض جلدية، فتوقف عن تناول محلول فنتكس، وأطلب نصيحة فورية من الطبيب وأخبره بأنك تتناول هذا الدواء. استشر طبيبك قبل وقف تناول محلول فنتكس. فإذا توقفت فجأة عن استعمال هذا الدواء فقد تصاب بنوبة قلبية</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يرتبط خطر هذه الآثار الجانبية الجلدية الخطيرة مع متغير في الجينات في الشخص الخاضع مع أصل صيني أو تايلندي، وإذا كنت من هذه الأصول وتم مسبقاً اختبار أنك تحمل هذا النوع الجيني (HLA-B*1502) ناقش ذلك مع طبيبك قبل استعمال محلول فنتكس.&nbsp;وقد يكون المرضى&nbsp;من ذوي البشرة السوداء في خطر أكبر من حصول مشاكل في الكبد لديهم، وتفاعلات جلدية خطيرة وتفاعلات تحسسية. وإذا كنت تتناول الفينيتوين في نفس الوقت الذي تتلقى فيه العلاج الإشعاعي لرأسك، وتم خفض جرعة دواء آخر يدعى الكورتيكوسيرويدات، فقد تزايد احتمالية حدوث طفح جلدي حاد يسمى حمامي متعدد الأشكال أو الذي يسبب تقرحات تسمى متلازمة ستيفنز جونسون أو انحلال البشرة النخري السمي (انظر الآثار الجانبية المحتملة في القسم 4)</p><p style="direction: rtl;">هناك عدد قليل من الأشخاص الذي يعالجون بمضادات الصرع مثل فينيتوين لديهم أفكار عن إيذاء أنفسهم أو قتل أنفسهم، وإذا كان لديك مثل هذه الأفكار في اي وقت، اتصل على الفور بطبيبك. أخبر طبيبك إذا كان أي من هذه الحالات ينطبق عليك حيث قد يعجل الفينيتوين أو يفاقم النوبات الصرعية المصحوبة بغيبة ونوبات الرمع العضلي (نوعان محددان من الصرع)</p><p style="direction: rtl;"><strong>:تناول الأدوية الأخرى ومحلول فنتكس</strong></p><p style="direction: rtl;">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أدوية أخرى بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية</p><p style="direction: rtl;">سيسمح هذا لطبيبك أن يقرر ما إذا كان إعطاءك الفينيتوين هو آمن بالنسبة لك</p><p style="direction: rtl;"><strong>:بعض الأدوية يمكن أن تؤثر على طريقة عمل محلول فنتكس أو أن فنتكس نفسه يمكن أن يقلل من فعالية الأدوية الأخرى التي تؤخذ في نفس الوقت. وتشمل هذه</strong></p><p style="direction: rtl;">الأدوية المستخدمة لعلاج الصرع أو النوبات (مثل الكاربامازبين، لاموتريجين، الفينوباربيتال، فالبروات الصوديوم وحمض الفالبرويك، توبيراميت، اوكسكاربازبين -</p><p style="direction: rtl;">سوكينايميديس بما في ذلك إيثوسكسيميد وفيغاباتربن)</p><p style="direction: rtl;">الكورتيكوستيرويدات على سبيل المثال بريدنيزولون (يستعمل في العديد من الحالات لمساعدة عملية علاج الجسم)-</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لعلاج الالتهابات الفطيرة (مثل الأمفوتريسين بي، والفلوكونازول، والإيتراكونازول، والكيتوكونازول، والبوزة كونازول، والفوريكونازول -</p><p style="direction: rtl;">والميكونازول)</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لعلاج أمراض الجلدية (مثل ميثوكسسالين)-</p><p style="direction: rtl;">الأدوية المستخدمة لعلاج السل وغيره من الأمراض (مثل الكلورامفينيكول، الأيزونيازيد، ريفامبيسين، السلفوناميدات، سلفاديازين، سلفاميتيزول، سلفاميثوكازول&nbsp;</p><p style="direction: rtl;">&nbsp;تريميثوبريم، سلفاثينازول، سليسوكسازول، دوكسيسيكلين وسيبروفلوكساسين)</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لعلاج الربو والتهاب الشعب الهوائية (مثل الثيوفيلين)-</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لمرض السكري (على سبيل المثال، تولبوتاميد)-</p><p style="direction: rtl;">الأدوية المستخدمة لارتفاع ضغط الدم (مثل حاصرات قنوات الكالسيوم مثل ديلتازيم، فيلوديبين)-</p><p style="direction: rtl;">الأدوية المستخدمة للألم والالتهاب (مثل فينيل بيتازون، الساليسيلات، بما في ذلك الاسبرين والمنشطات)-</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لقرحة المعدة وحرقة المعدة (على سبيل المثال أوميبرازول، سوكرالفات، الأدوية المعروفة بمضادات الحموضة مثل السيميتيدين، رانيتيدين، فاموتيدين وبعض مضادات الحموضة)</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة للأرق والاكتئاب والاضطرابات النفسية (مثل الكلورديازيبوكسيد، كلوزابين، الديازيبام، ديسولفيرام، الليثيوم، الميثادون، فلوكستين، فلوفوكسامين، سيرترالين، هالوبيريدول، ليفودوبا، باروكسيتين، ميثيلفيندييت، فينوثيازين، كيوتيابيني، ترازودون، ريزريربين، مضاد للاكتئاب اصطناعي ثلاثي الحلقات وفيلوكسازين)</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لعلاج السرطان (مثل العوامل المضادة للورم مثل تينيبوسيدي، فلورويوراسيل، كابسيتابين، بلوميسين، كاربوبلاتين، سيسبلاتين، دوكسوروبيسين وميثوتريكسات)</p><p style="direction: rtl;">الأدوية المستخدمة لمنع رفض زراعة الأعضاء والأنسجة (على سبيل المثال، سيكلوسبورين، تاكروليموس)-</p><p style="direction: rtl;">&nbsp; الأدوية المستخدمة في مشاكل القلب والدورة الدموية (مثل ديكومارول واميودارون وديجيتسوكين وديجوكسين ونيسولديبين وديسوبايراميد وميكسيليين&nbsp;وفيوروسيميد وكوينيدين وريسيربين وارفارين وحاصرات قنوات الكالسيوم بما في ذلك الديلتيازيم والنيفيديبين)</p><p style="direction: rtl;">الأدوية البديلة للهرمونات (الأستروجين) وموانع الحمل الفموية (حبوب منع الحمل)-</p><p style="direction: rtl;">الأدوية المستخدمة لخفض نسبة الكالسيوم في الدم والدهون والثلاثية (مثل أتورفاستاتين، فلوفاستاتين، سيمفاستاتين)-</p><p style="direction: rtl;">الأدوية المستخدمة في علاج الإصابة بفيروس نقص المناعة البشرية (مثل ديلافيردين وايفافيرينز وفوسامبرينافير وإندينافير ولوبينافير ونيلفينافير وريتونافير&nbsp;وساكوينافير)</p><p style="direction: rtl;">الأدوية المستخدمة لطرد الديدان الطفيلية من الجسم (على سبيل المثال البيندرازول، البرازيكوانتيل)-</p><p style="direction: rtl;">&nbsp;الأدوية المستخدمة لعلاج اضطرابات الغدة الدرقية (مثل هرمون الغدة الدرقية)-</p><p style="direction: rtl;">بعض الأدوية المستخدمة في العمليات، على سبيل المثال الهالوثين والميثادون (مخدر) وحاصرات عصبية وعضلية (تستخدم لتهدئة العضلات مثل البانكرونيوم&nbsp;والفيكورونيوم والوركين والسايتراكريوريوم)</p><p style="direction: rtl;">بعض المنتجات المتاحة بدون وصفة طبية (على سبيل المثال حمض الفوليك وفيتامين د) فيد يكون فحص الدم ضرورياً كل ستة أشهر لمراقبة كمية حمض الفوليك في الدم</p><p style="direction: rtl;">نبتة سانت جونز (العرب المثقوب، وهو عقار عشبي) يستعمل للقلق والاكتئاب في نفس وقت تناول هذا الدواء، إذا كنت قد تناولت بالفعل نبتة سانت جونز، عليك&nbsp;استشارة طبيبك قبل إيقاف مستحضرات نبتة سانت جونز</p><p style="direction: rtl;">مضادات التخثر، على سبيل المثال الوارفارين (حيث يمكن أن يعزز تأثيره بواسطة الفينيتوين)-</p><p style="direction: rtl;">قد يتدخل محلول فنتكس أيضاً في بعض الاختبارات المعملية التي قد تعطي لك</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>:تناول محلول فنتكس مع الطعام والشراب والكحول</strong></p><p style="direction: rtl;">تحدث إلى طبيبك قبل إعطائك هذا الدواء إذا كنت قد تناولت مؤخراً مشروباً كحولياً. حيث أن شرب الكثير من الكحول يمكن أن يؤثر أيضاً على تركيز الفينيتوين في الدم</p><p style="direction: rtl;"><strong>:الحمل والرضاعة الطبيعية والخصوبة</strong></p><p style="direction: rtl;">إذا كنت حاملاً أو تقومي بالإرضاع أو تعتقدي أنك حامل أو أنك تخططين لإنجاب طفل فعليك طلب النصيحة من طبيبك قبل تناول هذا الدواء</p><p style="direction: rtl;">إذا أصبحت حاملاً بالفعل وأنت تتناولين محلول فنتكس، يجب عليك إخبار طبيبك فوراً. من المهم أن تظل نوبات الصرع لديك مسيطر عليها بشكل جيد، لكن كما هو الحال مع أدوية مضادات الصرع الأخرى، فهناك خطر من أن تشكل ضرر على الجنين</p><p style="direction: rtl;">تأكد من أنك على وعي تام بخصوص مخاطر وفوائد تناول محلول فنتكس</p><p style="direction: rtl;">لا تتوقف عن أخذ محلول فنتكس حتى تراجع طبيبك حيث أنه من المهم التحكم في النوبات لديك. في حال تناولتي الفينيتوين خلال فترة الحمل فقد يؤثر على الجنين ولكن طبيبك قد يقرر أنه من المهم جداً أن تستمري في تناول الفينيتوين. سيوضح الطبيب أو الطبيبة لكي المخاطر من ذلك</p><p style="direction: rtl;">عند إطلاق الفينيتوين في حليب الثدي، يجب عليك عدم القيام بالإرضاع الطبيعي إذا تم إعطاؤك هذا الدواء</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>القيادات واستخدام الآلات</strong></p><p style="direction: rtl;">قد يسبب محلول فنتكس الدوخة أو النعاس. وإذا واجهت هذه الأعراض، يجب عليك أن تمتنع عن قيادة أو استخدام أي أدوات أو آلات.</p><p style="direction: rtl;">أطلب من طبيبك النصيحة قبل تناول أي دواء</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>يحتوي محلول فنتكس على إيثانول وصوديوم</strong></p><p style="direction: rtl;">يحتوي هذا المنتج على أقل من 1 مل مول صوديوم (23 ملغم) لكل جرعة، أي أنه &quot;خال من الصوديوم&quot; بشكل أساسي</p><p style="direction: rtl;">يحتوي هذا المنتج الطبي على 10% من الإيثانول (الكحول) أي ما يصل إلى 395.75 ملغم لكل جرعة،&nbsp;</p><p style="direction: rtl;">هذه النسبة من الكحول هي ضارة بالنسبة لأولئك الذين يعانون من إدمان الكحول، ويجب أن تؤخذ بعين الاعتبار في النساء الحوامل أو المرضعات والأطفال والمجموعات المعرضة للخطر مثل المرضى الذين يعانون من مرض الكبد أو نوبات الصرع</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">يتم إعطاء محلول فنتكس من قبل الطبيب أو الممرضة، ويمكن إعطاؤه ببطء في العضلات أو في الوريد، بدلاً من ذلك، يمكن تخفيفه وإعطاءه التنقيط أو التسريب في أحد الأوردة (عن طريق الوريد) وعندما تعطى كحقن في الوريد، يجب تخفيف محلول فنتكس بالمحلول الملحي العادي. ولا ينبغي أن يضاف محلول فنتكس العضلي أو الوريدي إلى دكستروز أو إلى محلول الدكستروز حيث يمكن أن يتداخل مع جرعة هذا الدواء. سيتم احتساب الجرعة الصحيحة من قبل الطبيب وفقاً لوزن جسمك وسيتم كتابتها كجرعة مكافئة من فينيتوين الصوديوم. تقدم الجرعة بالملغرام لكل جرعة إذا تم إعطاؤها كحقن أو بالملغرام لكل مليلتر من المحلول إذا تم إعطاؤها كتسريب. ويمكن إعطاء حقنة مكررة بعد 30 دقيقة إذا لزم الأمر</p><p style="direction: rtl;">خلال فترة العلاج، قد يقوم طبيبك بمراقبة مستويات الفينيتوين في الدم عن طريق أخذ عينات دم منتظمة، وفي بعض الأحيان، من الضروري إعطاء محلول فنتكس في العضل إذا لم يستطع الاستمرار في تناوله عن طريق الفم. ولا يستمر هذا عادة لأكثر من أسبوع واحد</p><p style="direction: rtl;">وعند تبديل تناول جرعة الفينيتوين عن طريق الفم لتكون عن طريق الحقن العضلي، يجب زيادة الجرعة بنسبة 50% تقريباً، عند التبديل مرة أخرى ليتم تناول الفينيتوين عن طريق الفم، ينبغي تخفيض الجرعة إلى نصف الجرعة الأصلية عن طريق الفم ولنفس الفترة الزمنية التي أعطيت فيها الجرعة بالحقن العضلي. هذا لأنه يتواصل إطلاق الفينيتوين من عضلاتك لبعض الوقت بعد إعطاء الحقن. الجرعة الموصي بها هل كما يلي</p><p style="direction: rtl;"><strong>للكبار</strong></p><p style="direction: rtl;"><strong>نوبة صرع شديد أو نوبة صرع (حالة صرعية)</strong></p><p style="direction: rtl;">تعطى جرعة من 10 إلى 15 ملغم لكل كيلوغرام من وزن الجسم عن طريق الوريد بمعدل لا تجاوز 50 ملغم في الدقيقة لدى البالغين، ويتبع ذلك المزيد من محلول فنتكس في كل 6 إلى 8 ساعات إما عن طريق الحقن أو عن طريق الفم</p><p style="direction: rtl;">إذا لم توقف محلول الفنتكس النوبات التي تعرضت لها، فستتم تجربة العلاجات الأخرى</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>عدم انتظام ضربات القلب (اختلاف في نبض القلب الطبيعي)</strong></p><p style="direction: rtl;">يتم إعطاء جرعة من 3.5 إلى 5 ملغم لكل كيلو غرام من وزن الجسم عن الوريد، بمعدل لا تتجاوز 50 ملغم في الدقيقة الواحدة. وقد يتكرر ذلك مرة ثانية</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>جراحة الأعصاب</strong></p><p style="direction: rtl;">يمكن إعطاء جرعة من 100 إلى 200 ملغم في العضل كل 4 ساعات تقريباً أثناء الجراحة ولمدة يومين إلى ثلاثة أيام بعد ذلك لمنع حدوث نوبات. ويمكن أن تخفض هذه الجرعة بعد ذلك إلى جرعة مداومة تصل إلى 300 ملغم يومياً ويتم ضبطها وفقاً لمستويات الدم لديك</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>كبار السن</strong></p><p style="direction: rtl;">قد تكون هناك حاجة إلى جرعات أخفض أو أقل تكراراً في بعض المرضى المسنين بسبب انخفاض التخلص من محلول فنتكس. قد لا يحتاج طبيبك إلى تغيير جرعتك، ولكن يمكن أن تحدث آثار جانبية أكثر عند كبار السن</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>مشاكل الكلى أو الكبد</strong></p><p style="direction: rtl;">تأكد من أن طبيبك يعرف ما إذا كان لديك مشاكل في الكبد أو الكلى حيث قد تحتاج إلى تعديل الجرعة</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>استعمال محلول فنتكس في الأطفال والمراهقين</strong></p><p style="direction: rtl;">ليس هناك حاجة لتعديل الجرعة ولكن الأطفال يميلون إلى تحطيم الدواء بشكل أسرع من البالغين وهذا قد يعني أن طبيبك يجب أن يغير عدد أو توقيت جرعات محلول فنتكس.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>استعمال محلول فنتكس في حديثي الولادة (أطفال صغار جداً) </strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">عادة ما تكون جرعة البدء من 15 إلى 20 ملغم لكل كيلو غرام من وزن الطفل. ويجب ألا يتم إعطاء محلول فنتكس في الوريد لحديثي الولادة بمعدل أسرع من 1 إلى 3 ملغم لكل كيلو غرام من وزن الجسم في الدقيقة الواحدة. ويتم امتصاص محلول فنتكس عن طريق الوريد بشكل أكثر موثوقية من فينيتوئين الفموي في الأطفال الصغار جداً.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا كنت تعتقد أنك أعطيت جرعة زائدة من محلول فنتكس أكثر مما ينبغي فعليك أن تخبر طبيبك على الفور</strong>.</p><p style="direction: rtl;">الجرعة الزائدة من محلول فنتكس تعتبر خطيرة. العلامات الأولية هي رأرأة العين (حالة حركة العين غير الطوعية)، إزدواج الرؤية (الرؤية المزدوجة)، الترنح (فقدان السيطرة الكاملة على حركات الجسم) والرتة (عسر التلفظ). علامات أخرى هي الهزة وضعف المنعكسات (تقلصات العضلات) والخمول والغثيان والتقيؤ. قد تصيب المريض غيبوبة وضغط الدم. الموت بسبب ضعف التنفس والدورة الدموية</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا كنت تعتقد أنك قد فاتتك جرعة من محلول فنتكس</strong></p><p style="direction: rtl;">إذا كنت تعتقد أنك قد فاتتك جرعة، أخبر طبيبك على الفور</p><p style="direction: rtl;">إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، أسأل طبيبك أو الممرضة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أثاراً جانبية، على الرغم من عدم حصول تلك الآثار لجميع من يتناولون هذا المحلول</p><p><strong><u>هام: إذا واجهت أياً من الأعراض الجانبية الخطيرة التالية، فاتصل بطبيبك على الفور</u></strong></p><p><strong>&nbsp;</strong>أزيز مفاجئ أو صعوبة في التنفس أو تورم الجفون أو الوجه أو الشفتين أو طفح جلدي أو حكة (خاصة إذا كانت تؤثر على كل الجسم). وهناك نسبة أعلى من هذا في المرضى السود</p><p><strong>&nbsp;</strong>إذا كنت تعاني من تغير في لون الجلد وتورم وألم في مكان إعطاءك الحقنة والذي يبدأ بعد ذلك ينتشر مع ذراعك إلى الأسفل بتجاه يديك وأصابعك. وقد يعني هذا أن لديك حالة تعرف باسم متلازمة القفاز الأرجواني. وفي معظم الحالات، سوف يتحسن هذا من تلقاء نفسه ولكن في بعض الحالات يمكن أن تكون الحالة خطيرة وتتطلب العلاج الطبي العاجل</p><p><strong>&nbsp;</strong>إذا أصبت بطفح جلدي يحتمل أن يهدد حياتك ويتسبب في حدوث تقرحات (يمكن أن يؤثر ذلك على الفم واللسان) وقد تكون هذه علامات على حالة تعرف باسم متلازمة ستيفنز جونسون أو انحلال البشرة السام. وقد ذكرنا أن هذه حالة نادرة جداً</p><p><strong>&nbsp;</strong>إذا لاحظت وجود كدمات أو حمى أو تبدو شاحباً أو لديك التهاب حاد في الحلق، فقد تكون هذه هي العلامات الأولى لوجود خلل في الدم، بما في ذلك انخفاض عدد خلايا الدم الحمراء أو الخلايا البيضاء أو الصفائح الدموية. وقد يأخذ الطبيب عينات دم منتظمة لاختبار هذه التأثيرات</p><p>الطفح الجلدي والحمى وتورم الغدد وزيادة في نوع من خلايا الدم البيضاء (فرط الحمضيات) والتهاب الأعضاء الداخلية (الكبد والرئتين والقلب والكليتين والأمعاء الغليظة)، وقد تعاني أيضاً من الألم والتهاب المفاصل، وقد تكون علامات تفاعل فرط الحساسية (على سبيل المثال تفاعلات والأمعاء الغليظة)، وقد تعاني أيضاً من الألم والتهاب المفاصل، وقد تكون علامات تفاعل فرط الحساسية على سبيل المثال تفاعلات دوائية أو الطفح الجلدي مع فرط الحمضيات والأعراض الجهازية) أو أن تكون ذات صلة بحالة تسمى الذئبة الحمامية الجهازية)</p><p><strong>&nbsp;</strong>إذا كنت تعاني من الارتباك أو الإصابة بمرض عقلي شديد، فقد يكون ذلك دليلاً على وجود كميات كبيرة من الفينيتوين في دمك. وفي حالات نادرة، عندما تظل كمية الفينيتوين في الدم عالية، فقد تحدث إصابة دماغية لا رجعة فيها. وقد يجري لك طبيبك اختبار دم لمعرفة كمية الفينيتوين الموجودة في الدم وقد يغير الجرعة</p><p><strong>:الآثار الجانبية الأخرى التي قد تحدث هي على النحو التالي</strong></p><p>حالات غير معروفة: لا يمكن تقدير تكرارها من البيانات المتاحة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثيرات على الجهاز العصبي: حركات العين غير المعتادة، عدم الثبات، صعوبة التحكم في الحركات، الاهتزاز، الحركات غير الطبيعية أو غير المنسقة، النطق غير السليم، الارتباك، الوخز والإبر أو الخدر، النعاس، الدوخة، الدوار، الأرق، العصبية، ارتعاش العضلات، الصداع، وتغير في التذوق</p><p>&nbsp; &nbsp;<strong>الآثار على الجلد: </strong>طفح جلدي يشمل طفح يشبه الحصبة والذي عادة ما يكون خفيفاً</p><p>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>الآثار على المعدة والأمعاء: </strong>الشعور بالغثيان، والمرض والإمساك</p><p>&nbsp; &nbsp; &nbsp;<strong>الآثار على الدم والجهاز اللمفاوي: </strong>تورم الغدد اللمفاوية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الآثار على الكبد والكلى:</strong> التهاب الكلى والكبد، تلف الكبد أو الفشل الكبدي الذي يمكن أن يؤدي إلى الوفاة (ينظر إليه على أنه اصفرار الجلد وبياض العين)، الكبد لا يؤدي وظيفته بشكل طبيعي</p><p>&nbsp; &nbsp;<strong>الآثار على الجهاز التناسلي والثدي: </strong>تغييرات في شكل القضيب، الانتصاب المؤلم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الآثار على اليدين والوجه والجسم:</strong> تغيرات في اليدين مع صعوبة في تقويم الأصابع والتغييرات في ملامح الوجه وتضخم الشفاه أو اللثة وزيادة أو شعر غير طبيعي في الجسم أو شعر الوجه</p><p>&nbsp; &nbsp;<strong>الآثار على الاختبارات الطبية: </strong>اختبارات وظائف الغدة الدرقية غير طبيعية</p><p><strong>الآثار على الجهاز التنفسي:</strong> مشاكل في التنفس بما في ذلك التوقف الكامل للتنفس، التهاب بطانة الرئة</p><p>&nbsp;&nbsp;<strong>الآثار على جهاز المناعة:</strong> مشاكل في دفاع الجسم ضد العدوى، التهاب جدار الشرايين</p><p>&nbsp; &nbsp;<strong>الآثار على القلب والدورة الدموية:</strong> انخفاض ضغط الدم وتضخم الأوعية الدموية. فقد ينخفض ضغط الدم لديك أيضاً وتواجه مشاكل في نبضات القلب عند حقن محلول فنتكس في الوريد بسرعة كبيرة</p><p>&nbsp; &nbsp;<strong>الآثار على العظام:</strong> هناك تقارير عن اضطرابات في العظام بما في ذلك هشاشة العظام ولين العظام (ترقق العظام) وكسور عليك استشارة طبيبك إذا كنت تتناول أدوية مضادة للصرع على المدى الطويل أو لديك تاريخ من هشاشة العظام أو تناول الستيرويدات</p><p>&nbsp; &nbsp; &nbsp;<strong>الآثار على موقع الحقن:</strong> قد يسبب تعاطي الفينيتوين العضلي الألم أو إيلام أو التصبغ أو تقشر خلايا الجلد وتشكل إصابة في موقع الحقن</p><p>&nbsp;</p><p><strong>يرجى مراجعة طبيبك: </strong>إذا لاحظت أياً من هذه الآثار الجانبية وأنها تسببت لك في قلق أو لاحظت أي آثار جانبية غير مدرجة في هذه النشرة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيداً عن متناول الأطفال</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورة على ملصق العبوة والكرتونة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور. ويجب حفظ العبوة بعيداً عن الضوء وتخزينها في درجة حرارة لا تتجاوز 30 درجة مئوية</p><p>إذا تم استخدام جزء من محتويات العبوة، فيجب التخلص من أي جزء متبقي لم يستخدم</p><p>لا يجب استخدام المحلول الذي يلاحظ فيه ضبابية في اللون أو رواسب</p><p>لا ينبغي خلط المحلول مع أي أدوية أخرى</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية، أسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي صوديوم الفينيتوين. يحتوي كل 1 مل من هذا المحلول على 50 ملغم من صوديوم الفينيتوين</p><p>المكونات الأخرى بروبيلين غليكول، كحول إيثيلي، هيدروكسيد الصوديوم، ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            محلول فنتكس عبارة عن محلول شفاف وعديم اللون وخالٍ من الجسميات. وكل علبة تحتوي على عشرة عبوات 5 مل من محلول فنتكس. 
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ام اس فارما السعودية &ndash; الرياض &ndash; المملكة العربية السعودية</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2020
SPM190280  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fentex 250mg /5ml solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial contains 250mg of Phenytoin as active substance.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. 
Clear and colorless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phenytoin Injection is indicated for the control of status epilepticus of the tonic-clonic (grand mal) type and prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>Status epilepticus : In a patient having continuous seizure activity, as compared to the more common rapidly recurring seizures, i.e. serial epilepsy, intravenous diazepam or a short-acting barbiturate is recommended prior to administration of phenytoin because of the more rapid onset of action of the former.</p><p>Following the use of diazepam in patients having continuous seizures and in the initial management of serial epilepsy a loading dose of phenytoin 10 - 15mg/kg should be injected slowly intravenously, at a rate not exceeding 50mg per minute in adults (this will require approximately 20 minutes in a 70kg patient). The loading dose should be followed by maintenance doses of 100mg orally or intravenously every 6 to 8 hours.</p><p>In neonates, it has been shown that absorption of phenytoin is unreliable after oral administration, but a loading dose of 15-20mg/kg of phenytoin intravenously will usually produce serum concentrations of 10&ndash;20 mg/l phenytoin which is within the generally accepted therapeutic range. The drug should be injected slowly intravenously at a rate of 1-3mg/kg/min.</p><p>Determination of phenytoin serum levels is advised during use in the management of status epilepticus and</p><p>subsequently whilst establishing maintenance dosage. The clinically effective range is usually 10- 20mg/1 although some cases of tonic-clonic seizures may be controlled with lower serum levels of phenytoin.</p><p>Intramuscular administration should not be used in the treatment of status epilepticus because peak plasma levels may not be reached for up to 24 hours.</p><p>Other clinical conditions: It is not possible to provide a universally applicable dosage schedule.</p><p>The intravenous route of administration is preferred. Dosage and dosing interval will be determined by the needs of the individual patient and factors such as previous anti-epileptic therapy, seizure control, age and general medical condition must be considered.</p><p>Although absorption of phenytoin is slow following i.m. injection, such use may be appropriate in certain conditions.</p><p>When short-term intramuscular administration is necessary for a patient previously stabilised orally, compensating dosage adjustments are essential to maintain therapeutic serum levels. An intramuscular dose 50% greater than the oral dose is necessary to maintain these levels. When returned to oral administration, the dose should be reduced by 50% of the original oral dose, for the same period of time the patient received phenytoin intramuscularly. This is to prevent excessive serum levels due to continued release from intramuscular tissue sites</p><p>Neurosurgery: In a patient who has not previously received the drug, Phenytoin Injection 100 - 200mg (2 - 4ml) may be given intramuscularly at approximately 4-hour intervals prophylactically during neurosurgery and continued during the postoperative period for 48 - 72 hours. The dosage should then be reduced to a maintenance dose of 300mg and adjusted according to serum level estimations.</p><p>If possible, intramuscular injections of phenytoin should not be continued for more than one week; after this,</p><p>alternative routes such as naso-gastric intubation should be considered. For time periods less than one week, the&nbsp; patient switched from intramuscular administration should receive half the original oral dose for the same period of time the patient received phenytoin intramuscularly. Measurement of serum levels is of value as a guide to an appropriate adjustment of dosage.</p><p>&nbsp;</p><p>Elderly: (over 65 years): Phenytoin clearance may be decreased in elderly patients. Lower or less frequent dosing may be required (see section 5.2). It should be noted that complications may occur more readily in elderly patients.</p><p>&nbsp;</p><p>Pediatric population</p><p>Neonates: In neonates it has been shown that absorption of phenytoin is unreliable after oral administration, but a loading dose of phenytoin injected slowly intravenously at a rate of 1-3mg/kg/min at a dose of 15-20mg/kg will usually produce serum concentrations of phenytoin within the generally accepted therapeutic range of 10-20mg/l.</p><p>Infants and children: Children tend to metabolize phenytoin more rapidly than adults. This should be considered when determining dosage regimens; monitoring serum levels is therefore particularly beneficial in such cases.</p><p>&nbsp;</p><p>Method of administration: Intravenous. Intramuscular.</p><p>Solutions for parenteral administration should be inspected visually for particulate matter and discoloration prior to use. Only a clear solution should be used and the product should be discarded if a precipitate or haziness develops in the solution. On refrigeration or freezing, a precipitate might form, but this will dissolve when the solution is allowed to stand at room temperature. The product is still suitable for use. Only a clear solution should be used. A faint yellow discoloration may develop, but this does not affect the potency of the solution.</p><p>There is a relatively small margin between full therapeutic effect and minimally toxic doses of this drug. Optimum control without clinical signs of toxicity can most often be achieved with serum levels in the range 10 - 20mg/1 (40 &ndash; 80 micromoles/1).</p><p>Because of the risk of local toxicity, intravenous phenytoin should be injected slowly directly into a large vein through a large-gauge needle or intravenous catheter.</p><p>Each injection or infusion of intravenous phenytoin should be preceded and followed by an injection of sterile saline through the same needle or catheter to avoid local venous irritation due to alkalinity of the solution. (See section 4.4)</p><p>For administration by intravenous infusion phenytoin injection should be diluted in 50 - 100 ml of normal saline, and the final concentration of phenytoin in the solution should not exceed 10 mg/ml, the infusion mixture should not be refrigerated. Administration should commence immediately after the mixture has been prepared and must be completed within one hour (the infusion mixture should not be refrigerated). An in-line filter (0.22 - 0.50 microns) should be used. The diluted form is suitable for use as long as it remains free of haziness and precipitate.</p><p>Phenytoin should neither be mixed with other drugs nor be added to dextrose or dextrose-containing solutions due to the potential for precipitation of phenytoin acid.</p><p>Continuous monitoring of the electrocardiogram and blood pressure is essential and the patient should be observed for signs of respiratory depression. Cardiac resuscitative equipment should be available. If administration of intravenous phenytoin does not terminate seizures, the use of other measures, including general anaesthesia should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, other hydantoins or to any of the excipients listed in section 6.1
Because of its effect on ventricular automaticity, it is also contra-indicated in sinus bradycardia, sino-atrial block, and second and third degree A-V block, and patients with Adams-Stokes syndrome. Intra-arterial injection must be avoided because of the high pH of the solution.
Co-administration of phenytoin is contraindicated with delavirdine due to the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General</p><p>In adults, intravenous administration should not exceed a rate of 50mg per minute. In neonates, phenytoin should be administered at a rate of 1 - 3mg/kg/min.</p><p>Hypotension usually occurs with rapid administration of phenytoin by the intravenous route. Irritation and inflammation of soft tissue has occurred at the injection site with and without extravasation of intravenous phenytoin. Soft tissue irritation may vary from slight tenderness to extensive necrosis, sloughing and in rare instances has led to amputation.</p><p>Subcutaneous or perivascular injection should be avoided because of the highly alkaline nature of the solution.</p><p>The intramuscular route is not recommended for the treatment of status epilepticus because of slow absorption.</p><p>Serum levels of phenytoin in the therapeutic range cannot be rapidly achieved by this method.</p><p>Intravenous phenytoin should be used with caution in patients with hypotension and severe myocardial insufficiency.</p><p>Antiepileptic drugs should not be abruptly discontinued because of the possibility of increased seizure frequency, including status epilepticus. When, in the judgement of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class.</p><p>Acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.</p><p>Phenytoin may precipitate or aggravate absence seizures and myoclonic seizures.</p><p>Because phenytoin is highly protein bound and extensively metabolised by the liver, reduced maintenance dosage may be required in patients with impaired liver function to prevent accumulation and toxicity. Where protein binding is reduced, as in uraemia, total serum phenytoin levels will be reduced accordingly. However, as the pharmacologically active free drug concentration is unlikely to be altered, under these circumstances therapeutic control may be achieved with total phenytoin levels below the normal range 10 - 20mg/l.</p><p>Dosage should not exceed the minimum necessary to control convulsions.</p><p>Due to an increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with</p><p>hypoalbuminemia, the interpretation of total plasma phenytoin concentrations should be made with caution. Unbound concentration of phenytoin may be elevated in patients with hyperbilirubinemia. Unbound phenytoin concentrations may be more useful in these patient populations.</p><p>&nbsp;</p><p>Cardiovascular Effect</p><p>The most significant signs of toxicity with the intravenous use of phenytoin are cardiovascular collapse and/or central nervous system depression. Severe cardiotoxic reactions and fatalities due to depression of atrial and ventricular conduction and ventricular fibrillation, respiratory arrest and tonic seizures have been reported, particularly in elderly or gravely ill patients, if the preparation is given too rapidly or in excess.</p><p>Anticonvulsant Hypersensitivity Syndrome/ Drug Reaction with Eosinophilia and Systemic Symptoms (AHS/DRESS):</p><p>Anticonvulsant Hypersensitivity Syndrome (AHS) is a rare drug-induced, multiorgan syndrome that is potentially fatal and occurs in some patients taking anticonvulsant medication, including phenytoin. AHS/DRESS typically, although not exclusively is characterized by fever, rash, lymphadenopathy, and other multiorgan pathologies, such as hepatitis, nephritis, haematological abnormalities, myocarditis, myositis or pneumonitis. Initial symptoms may resemble an acute viral infection. Other common manifestations include arthralgias, jaundice, hepatomegaly, leucocytosis, and eosinophilia. The mechanism is unknown. The interval between first drug exposure and symptoms is usually 2-4 weeks, but has been reported in individuals receiving anticonvulsants for 3 or more months. If such signs and symptoms occur, the patient should be evaluated immediately. Phenytoin should be discontinued if an alternative aetiology for the signs and symptoms cannot be established. Drug rash with eosinophilia and systemic symptoms</p><p>(DRESS) reflects a serious hypersensitivity reaction to drugs, characterized by skin rash, fever, lymph node</p><p>enlargement, and internal organ involvement. Cases of DRESS have been noted in patients taking phenytoin.</p><p>Patients at higher risk for developing AHS/DRESS include black patients, patients who have a family history of or who have experienced this syndrome in the past (with phenytoin or other anticonvulsant drugs), and immuno-suppressed patients. The syndrome is more severe in previously sensitized individuals. If a patient is diagnosed with AHS, discontinue the phenytoin and provide appropriate supportive measures.</p><p>Serious skin reactions:</p><p>Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Phenytoin.</p><p>Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS and TEN is within the first weeks of treatment.</p><p>If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Phenytoin sodium treatment should be discontinued.</p><p>The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.</p><p>If the patient has developed SJS or TEN with the use of Phenytoin and it must not be re-started in this patient at any time.</p><p>The physician should advise the patient to discontinue treatment if the rash appears. If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further phenytoin medication is contraindicated.</p><p>Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should seek medical advice from their physician immediately when observing any indicative signs or symptoms.</p><p>Several individual case reports have suggested that there may be an increased, although still rare, incidence of</p><p>hypersensitivity reactions, including skin rash and hepatotoxicity, in black patients.</p><p>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding use of drugs associated with SJS/TEN, including phenytoin, in HLA-B*1502 positive patients when alternative therapies are otherwise equally available.</p><p>Literature reports suggest that the combination of phenytoin, cranial irradiation, and the gradual reduction of</p><p>corticosteroids may be associated with the development of erythema multiforme and/or SJS and/or TEN.</p><p>Local Toxicity (including Purple Glove Syndrome)</p><p>Soft tissue irritation and inflammation have occurred at the site of injection with and without extravasation of</p><p>intravenous phenytoin.</p><p>Oedema, discoloration and pain distal to the site of injection (described as &ldquo;purple glove syndrome&rdquo;) have been</p><p>reported following peripheral intravenous phenytoin injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing of skin. The syndrome may not develop for several days after injection. Although resolution of symptoms may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting and in rare cases, amputation.</p><p>Improper administration including subcutaneous or perivascular injection should be avoided.</p><p>Intramuscular phenytoin administration may cause pain, necrosis, and abscess formation at the injection site (see section 4.2).</p><p>Phenytoin is not effective for absence (petit mal) seizures. If tonic-clonic (grand mal) and absence (petit mal) seizures are present together, combined drug therapy is needed.</p><p>&nbsp;</p><p>Central Nervous System Effect</p><p>Serum levels of phenytoin sustained above the optimal range may produce confusional states referred to as &#39;delirium&#39;, &#39;psychosis&#39; or &#39;encephalopathy&#39; or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum drug level determinations are recommended. Dose reduction of phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination of therapy with phenytoin is recommended.</p><p>Herbal preparations containing St. John&#39;s wort (Hypericum perforatum) should not be used while taking phenytoin due to the risk of decreased plasma concentrations and reduced clinical effects of phenytoin (see section 4.5)</p><p>Hepatic Injury</p><p>Biotransformation of phenytoin occurs mainly in the liver.</p><p>Toxic hepatitis and liver damage have been reported and may, in rare cases, be fatal.</p><p>Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin.</p><p>These incidents usually occur within the first 2 months of treatment and may be associated with AHS/DRESS (see section 4.4).</p><p>Patients with impaired hepatic function, the elderly, or those who are gravely ill may show early signs of toxicity.</p><p>The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered.</p><p>The risk of hepatotoxicity and other hypersensitivity reactions to phenytoin may be higher in black patients.</p><p>Haematopoietic System</p><p>Haematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis and pancytopenia with or without bone marrow suppression.</p><p>Metabolic Effect</p><p>Phenytoin may affect glucose metabolism and inhibit insulin release. Hyperglycaemia has been reported. Phenytoin is not indicated for seizures due to hypoglycaemia or other metabolic causes. Caution is advised when treating patients with diabetes.</p><p>There are isolated reports associating phenytoin with exacerbation of porphyria, therefore, caution should be</p><p>exercised when using phenytoin in patients with porphyria.</p><p>Suicide</p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications.</p><p>A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Phenytoin.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>Laboratory tests: It may be necessary to measure serum phenytoin levels to achieve optimal dosage adjustments.</p><p>This product contains a number of excipients known to have a recognized action or effect. These are:</p><p>&bull; Sodium: This medicinal product contains less than 1mmol sodium (23mg) per dose i.e. essentially &#39;sodium-free&#39;</p><p>&bull; Ethanol (395.75 mg/5 ml):- This may be harmful for those suffering from alcoholism and should be taken into</p><p>account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Drug Interactions:</em></p><p>Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement. Phenytoin is metabolized by hepatic cytochrome (CYP) P450 enzymes CYP2C9 and CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.</p><p>Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes and may reduce the levels of drugs metabolized by these enzymes.</p><p>There are many drugs which may increase or decrease serum phenytoin levels or which phenytoin may affect. Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected.</p><p>The most commonly occurring drug interactions are listed below.</p><p><strong><u>Drugs which may increase phenytoin serum levels</u></strong></p><p>Table 1 summarizes the drug classes which may potentially increase phenytoin serum levels.</p><p><strong>Table 1 Drugs Which May Increase Phenytoin Serum Levels</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Drug Classes</strong></p></td><td style="vertical-align:top"><p><strong>Drugs in each Class (such as) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Alcohol (acute intake)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Analgesic/Anti-inflammatory agents</p></td><td style="vertical-align:top"><p>azapropazone</p><p>phenylbutazone</p><p>salicylates</p></td></tr><tr><td style="vertical-align:top"><p>Anesthetics</p></td><td style="vertical-align:top"><p>halothane</p></td></tr><tr><td style="vertical-align:top"><p>Antibacterial agents</p></td><td style="vertical-align:top"><p>chloramphenicol</p><p>erythromycin</p><p>isoniazid</p><p>sulfadiazine</p><p>sulfamethizole</p><p>sulfamethoxazole-trimethoprim</p><p>sulfaphenazole</p><p>sulfisoxazole</p><p>sulfonamides</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p></td><td style="vertical-align:top"><p>felbamate</p><p>oxcarbazepine</p><p>sodium valproate</p><p>succinimides</p><p>topiramate</p></td></tr><tr><td style="vertical-align:top"><p>Antifungal agents</p></td><td style="vertical-align:top"><p>amphotericin B</p><p>fluconazole</p><p>itraconazole</p><p>ketoconazole</p><p>miconazole</p><p>voriconazole</p></td></tr><tr><td style="vertical-align:top"><p>Antineoplastic agents</p></td><td style="vertical-align:top"><p>fluorouracil</p><p>capecitabine</p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines/Psychotropic agents</p></td><td style="vertical-align:top"><p>chlordiazepoxide</p><p>diazepam</p><p>disulfiram</p><p>methylphenidate</p><p>trazodone</p><p>viloxazine</p></td></tr><tr><td style="vertical-align:top"><p>Calcium channel blockers/Cardiovascular agents</p></td><td style="vertical-align:top"><p>amiodarone</p><p>dicumarol</p><p>diltiazem</p><p>nifedipine</p><p>ticlopidine</p></td></tr><tr><td style="vertical-align:top"><p>H2-antagonists</p></td><td style="vertical-align:top"><p>cimetidine</p></td></tr><tr><td style="vertical-align:top"><p>HMG-CoA reductase inhibitors</p></td><td style="vertical-align:top"><p>fluvastatin</p></td></tr><tr><td style="vertical-align:top"><p>Hormones</p></td><td style="vertical-align:top"><p>oestrogens</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressant drugs</p></td><td style="vertical-align:top"><p>tacrolimus</p></td></tr><tr><td style="vertical-align:top"><p>Oral hypoglycemic agents</p></td><td style="vertical-align:top"><p>tolbutamide</p></td></tr><tr><td style="vertical-align:top"><p>Proton pump inhibitors</p></td><td style="vertical-align:top"><p>omeprazole</p></td></tr><tr><td style="vertical-align:top"><p>Serotonin re-uptake inhibitors</p></td><td style="vertical-align:top"><p>fluoxetine</p><p>fluvoxamine</p><p>sertraline</p></td></tr></tbody></table><p><strong><u>Drugs which may decrease phenytoin serum levels</u></strong></p><p>Table 2 summarizes the drug classes which may potentially decrease phenytoin serum levels.</p><p><strong>Table 2 Drugs Which May Decrease Phenytoin Serum Levels</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Drug Classes</strong></p></td><td style="vertical-align:top"><p><strong>Drugs in each Class (such as) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Alcohol (chronic intake)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Antibacterial agents</p></td><td style="vertical-align:top"><p>rifampin</p><p>ciprofloxacin</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p></td><td style="vertical-align:top"><p>vigabatrin</p></td></tr><tr><td style="vertical-align:top"><p>Antineoplastic agents</p></td><td style="vertical-align:top"><p>bleomycin</p><p>carboplatin</p><p>cisplatin</p><p>doxorubicin</p><p>methotrexate</p></td></tr><tr><td style="vertical-align:top"><p>Antiretrovirals</p></td><td style="vertical-align:top"><p>fosamprenavir</p><p>nelfinav</p><p>ritonavir</p></td></tr><tr><td style="vertical-align:top"><p>Bronchodilators</p></td><td style="vertical-align:top"><p>theophylline</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular agents</p></td><td style="vertical-align:top"><p>reserpine</p></td></tr><tr><td style="vertical-align:top"><p>Folic Acid</p></td><td style="vertical-align:top"><p>folic acid</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemic agents</p></td><td style="vertical-align:top"><p>diazoxide</p></td></tr><tr><td style="vertical-align:top"><p>St. John&#39;s Wort</p></td><td style="vertical-align:top"><p>St. John&#39;s wort</p></td></tr></tbody></table><p>Serum levels of phenytoin can be reduced by concomitant use of the herbal preparations containing St. John&#39;s wort (Hypericum perforatum).</p><p>This is due to induction of drug metabolising enzymes by St. John&#39;s wort. Herbal preparations containing St. John&#39;s wort should therefore not be combined with phenytoin. The inducing effect may persist for at least 2 weeks after cessation of treatment with St. John&#39;s wort. If a patient is already taking St. John&#39;s wort check the anticonvulsant levels and stop St. John&#39;s wort. Anticonvulsant levels may increase on stopping St. John&#39;s wort. The dose of anticonvulsant may need adjusting.</p><p><strong><u>Drugs which may increase or decrease phenytoin serum levels</u></strong></p><p>Table 3 summarizes the drug classes which may either increase or decrease phenytoin serum levels.</p><p><strong>Table 3 Drugs Which May Increase or Decrease Phenytoin Serum Levels</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Drug Classes</strong></p></td><td style="vertical-align:top"><p><strong>Drugs in each Class (such as) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Antibacterial agents</p></td><td style="vertical-align:top"><p>ciprofloxacin</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p></td><td style="vertical-align:top"><p>carbamazepine</p><p>phenobarbital</p><p>sodium valproate</p><p>valproic acid</p></td></tr><tr><td style="vertical-align:top"><p>Antineoplastic agents</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychotropic agents</p></td><td style="vertical-align:top"><p>chlordiazepoxide</p><p>diazepam</p><p>phenothiazines</p></td></tr></tbody></table><p><strong><u>Drugs whose serum levels and/or effects may be altered by phenytoin</u></strong></p><p>Table 4 summarizes the drug classes whose serum levels and/or effects may be altered by phenytoin.</p><p><strong>Table 4 Drugs Whose Serum Levels and/or Effects May be Altered by Phenytoin</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Drug Classes</strong></p></td><td style="vertical-align:top"><p><strong>Drugs in each Class (such as) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Antibacterial agents</p></td><td style="vertical-align:top"><p>doxycycline</p><p>rifampin</p><p>tetracycline</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p></td><td style="vertical-align:top"><p>carbamazepine</p><p>lamotrigine</p><p>phenobarbital</p><p>sodium valproate</p><p>valproic acid</p></td></tr><tr><td style="vertical-align:top"><p>Antifungal agents</p></td><td style="vertical-align:top"><p>azoles</p><p>posaconazole</p><p>voriconazole</p></td></tr><tr><td style="vertical-align:top"><p>Antihelmintics</p></td><td style="vertical-align:top"><p>albendazole</p><p>praziquantel</p></td></tr><tr><td style="vertical-align:top"><p>Antineoplastic agents</p></td><td style="vertical-align:top"><p>teniposide</p></td></tr><tr><td style="vertical-align:top"><p>Antiretrovirals</p></td><td style="vertical-align:top"><p>delavirdine</p><p>efavirenz</p><p>fosamprenavir</p><p>indinavir</p><p>lopinavir/ritonavir</p><p>nelfinavir</p><p>ritonavir</p><p>saquinavir</p></td></tr><tr><td style="vertical-align:top"><p>Bronchodilators</p></td><td style="vertical-align:top"><p>theophylline</p></td></tr><tr><td style="vertical-align:top"><p>Calcium channel blockers/Cardiovascular agents</p></td><td style="vertical-align:top"><p>digitoxin</p><p>digoxin</p><p>mexiletine</p><p>nicardipine</p><p>nimodipine</p><p>nisoldipine</p><p>quinidine</p><p>verapamil</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Coumarin anticoagulants</p></td><td style="vertical-align:top"><p>warfarin</p></td></tr><tr><td style="vertical-align:top"><p>Cyclosporine</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diuretics</p></td><td style="vertical-align:top"><p>furosemide</p></td></tr><tr><td style="vertical-align:top"><p>HMG-CoA reductase inhibitors</p></td><td style="vertical-align:top"><p>atorvastatin</p><p>fluvastatin</p><p>simvastatin</p></td></tr><tr><td style="vertical-align:top"><p>Hormones</p></td><td style="vertical-align:top"><p>oestrogens</p><p>oral contraceptives</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemic agents</p></td><td style="vertical-align:top"><p>diazoxide</p></td></tr><tr><td style="vertical-align:top"><p>Neuromuscular blocking agents</p></td><td style="vertical-align:top"><p>alcuronium</p><p>cisatracurium</p><p>pancuronium</p><p>rocuronium</p><p>vecuronium</p></td></tr><tr><td style="vertical-align:top"><p>Opioid analgesics</p></td><td style="vertical-align:top"><p>methadone</p></td></tr><tr><td style="vertical-align:top"><p>Oral hypoglycemic agents</p></td><td style="vertical-align:top"><p>chlorpropamide</p><p>glyburide</p><p>tolbutamide</p></td></tr><tr><td style="vertical-align:top"><p>Psychotropic agents/Antidepressants</p></td><td style="vertical-align:top"><p>clozapine</p><p>paroxetine</p><p>quetiapine</p><p>sertraline</p></td></tr><tr><td style="vertical-align:top"><p>Vitamin D</p></td><td style="vertical-align:top"><p>vitamin D</p></td></tr></tbody></table><p>Although not a true pharmacokinetic interaction, tricyclic antidepressants and phenothiazines may precipitate seizures in susceptible patients and phenytoin dosage may need to be adjusted.</p><p><strong><u>Drug/Laboratory Test Interactions:</u></strong></p><p>Phenytoin may cause a slight decrease in serum levels of total and free thyroxine, possibly as a result of enhanced peripheral metabolism.</p><p>These changes do not lead to clinical hypothyroidism and do not affect the levels of circulating TSH. The latter can therefore be used for diagnosing hypothyroidism in the patient on phenytoin. Phenytoin does not interfere with uptake and suppression tests used in the diagnosis of hypothyroidism.</p><p>It may, however, produce lower than normal values for dexamethasone or metapyrone tests. Phenytoin may cause raised serum levels of glucose, alkaline phosphatase, gamma glutamic transpeptidase and lowered serum levels of calcium and folic acid. It is recommended that serum folate concentrations be measured at least every 6 months, and folic acid supplements given if necessary. Phenytoin may affect blood sugar metabolism tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>In considering the use of Fentex intravenously in the management of status epilepticus in pregnancy, the following information should be weighed in assessing the risks and the benefits. The potential adverse effects upon the foetus of status epilepticus, specifically hypoxia, make it imperative to control the condition in the shortest possible time.</p><p>There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans. Genetic factors or the epileptic condition itself may be more important than drug therapy in leading to birth defects.</p><p>The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus and attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or foetus.</p><p>There is some evidence that phenytoin may produce congenital abnormalities in the offspring of a small number of epileptic patients, therefore it should not be used as the first drug during pregnancy, especially early pregnancy, unless in the judgement of the physician the potential benefits outweigh the risk.</p><p>In addition to the reports of increased incidence of congenital malformations, such as cleft lip/palate and heart malformations in children of women receiving phenytoin and other antiepileptic drugs, there have been recent reports of a foetal hydantoin syndrome. This consists of pre-natal growth deficiency, microencephaly and mental deficiency in children born to mothers who have received phenytoin, barbiturates, alcohol, or trimethadione. However, these features are all interrelated and are frequently associated with intrauterine growth retardation from other causes.</p><p>There have been isolated reports of malignancies, including neuroblastoma, in children whose mothers received phenytoin during pregnancy.</p><p>An increase in seizure frequency during pregnancy occurs in a proportion of patients, because of altered phenytoin absorption or metabolism.</p><p>Periodic measurement of serum phenytoin levels is particularly valuable in the management of a pregnant epileptic patient as a guide to an appropriate adjustment of dosage. However, postpartum restoration of the original dosage will probably be indicated. Neonatal coagulation defects have been reported within the first 24 hours in babies born to epileptic mothers receiving phenytoin. Vitamin K has been shown to prevent or correct this defect and may be given to the mother before delivery and to the neonate after birth.</p><p><em>Breast-feeding</em></p><p>Infant breast-feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is recommended in patients performing skilled tasks (e.g. driving or operating machines) as treatment with phenytoin may cause central nervous system adverse effects such as dizziness and drowsiness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions have been reported with phenytoin (frequency unknown &ndash; cannot be estimated from available data):</p><p>Signs of toxicity are associated with cardiovascular and central nervous system depression.</p><p><em>Central Nervous System:</em></p><p>Adverse reactions in this body system are common and are usually dose-related. Reactions include nystagmus, ataxia, slurred speech, decreased coordination and mental confusion. Cerebellar atrophy has been reported, and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use. Dizziness, vertigo, insomnia, transient nervousness, motor twitchings, headache, paraesthesia somnolence drowsiness and taste perversion have also been observed</p><p>There have also been rare reports of phenytoin-induced dyskinesia, including chorea, dystonia, tremor, and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs. A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. Tonic seizures have also been reported.</p><p><em>Cardiovascular System:</em></p><p>Severe cardiotoxic reactions and fatalities have been reported with atrial and ventricular conduction depression and ventricular fibrillation. Severe complications are most commonly encountered in older people or gravely ill patients.</p><p><em>Immune system reactions:</em></p><p>Anaphylactoid reaction and anaphylaxis.</p><p><em>Respiratory:</em></p><p>Alterations in respiratory function including respiratory arrest may occur.</p><p><em>Injection Site:</em></p><p>Local irritation, inflammation, tenderness, necrosis, and sloughing of skin have been reported with or without extravasation of intravenous phenytoin. Edema, discoloration and pain distal to the site of injection (described as &ldquo;purple glove syndrome&rdquo;) have also been reported.</p><p><em>Dermatological System:</em></p><p>Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes. A morbilliform rash (measles-like) is the most common. Other types of dermatitis are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, lupus erythematosus. Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported very rarely.</p><p><em>Haematopoietic System:</em></p><p>Haematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression and aplastic anaemia. While macrocytosis and megaloblastic anaemia have occurred, these conditions usually respond to folic acid therapy. There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy (local or generalised) including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin&#39;s disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling serum sickness, e.g. fever, rash and liver involvement.</p><p>In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs.</p><p><em>Gastrointestinal System:</em></p><p>Acute hepatic failure, toxic hepatitis, liver damage, vomiting, nausea, constipation.</p><p><em>Connective Tissue System:</em></p><p>Coarsening of the facial features, enlargement of the lips, gingival hyperplasia, hirsutism, hypertrichosis, Peyronie&#39;s disease and Dupuytren&#39;s contracture may occur rarely.</p><p><em>Immune System:</em></p><p>Hypersensitivity syndrome/Drug reaction with eosinophilia and systemic symptoms (HSS/DRESS) has been reported and may in rare cases be fatal (the syndrome may include, but is not limited to, symptoms such as arthralgias, eosinophilia, fever, liver dysfunction, lymphadenopathy or rash), systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities may occur.</p><p>Several individual case reports have suggested that there may be an increased, although still rare, incidence of hypersensitivity reactions, including skin rash and hepatotoxicity, in black patients.</p><p><em>Musculoskeletal System:</em></p><p>There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with phenytoin. The mechanism by which phenytoin affects bone metabolism has not been identified.</p><p><em>Other:</em></p><p>Polyarthropathy, interstitial nephritis, pneumonitis.</p><p><em>Paediatric population </em></p><p>The adverse event profile of phenytoin is generally similar between children and adults. Gingival hyperplasia occurs more frequently in pediatric patients and in patients with poor oral hygiene.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The lethal dose in children is not known. The mean lethal dose in adults is estimated to be 2 to 5 g. The initial symptoms are nystagmus, ataxia and dysarthria. Other signs are tremor, hyperflexia, lethargy, nausea, vomiting. The patient may become comatose and hypotensive. Death is due to respiratory and circulatory depression.</p><p>Attempts to relate serum levels of the drug to toxic effects have shown wide interpatient variation. Nystagmus on lateral gaze usually appears at 20 mg/l, and ataxia at 30 mg/l, dysarthria and lethargy appear when the serum concentration is &gt;40 mg/l, but a concentration as high as 50 mg/l has been reported without evidence of toxicity.</p><p>As much as 25 times the therapeutic dose, which resulted in a serum concentration of 100 mg/l, was taken with complete recovery. Irreversible cerebellar dysfunction and atrophy have been reported.</p><p><em>Treatment:</em></p><p>Treatment is non-specific since there is no known antidote.</p><p>The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed.</p><p>Haemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in children.</p><p>In acute overdosage the possibility of the presence of other CNS depressants, including alcohol, should be borne in mind.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: N03AB02</p><p><strong>Mechanism of action</strong></p><p>The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>A fall in serum levels may occur when patients are changed from oral to intramuscular administration. The drop is caused by slower absorption, as compared to oral administration, because of the poor water solubility of phenytoin. Intravenous administration is the preferred route for producing rapid therapeutic serum levels.</p><p>Patients stabilized on a daily oral regimen of phenytoin experience a drop in peak blood levels to 50-60 percent of stable levels if crossed over to an equal dose administered intramuscularly. However, the intramuscular depot of poorly soluble material is eventually absorbed, as determined by urinary excretion of 5 (p-hydroxyphenyl)-5-phenylhydantoin (HPPH), the principal metabolite, as well as the total amount of drug eventually appearing in the blood. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal.</p><p>A short-term (one week) study indicates that patients do not experience the expected drop in blood levels when crossed over to the intramuscular route if the phenytoin IM dose is increased by 50 percent over the previously established oral dose. To avoid drug accumulation caused by absorption from the muscle depots, it is recommended that for the first week back on oral phenytoin, the dose be reduced to half of the original oral dose (one-third of the IM dose). Experience for periods greater than one week is lacking and blood level monitoring is recommended.</p><p>Therapeutic effect without clinical signs of toxicity occurs most often with serum total concentrations between 10 and 20 mcg/mL (unbound phenytoin concentrations of 1 to 2 mcg/mL).</p><p><u>Distribution</u></p><p>Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement.</p><p><u>Elimination</u></p><p>The serum half-life in man after intravenous administration ranges from 10 to 15 hours.</p><p><u>Metabolism</u></p><p>Phenytoin is metabolized by the cytochrome P450 enzymes CYP2C9 and CYP2C19.</p><p><u>Excretion</u></p><p>Most of the drug is excreted in the bile as inactive metabolites. Urinary excretion of phenytoin and its metabolites occurs partly by glomerular filtration but, more importantly, by tubular secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propylene glycol, Ethyl alcohol, Sodium hydroxide and Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fentex Should not be mixed with other drugs because of precipitation of Phenytoin acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Keep the vial in the outer carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear tubular glass vials 6R Type I, Rubber stopper 20mm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For I.V. and I.M. administration.</p><p>Use as directed by the physician.</p><p>Solutions in which a haziness or precipitate develops should not be used.</p><p>Do not mix with other drugs because of precipitation of phenytoin acid.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi 
 Riyadh-kingdom of Saudi Arabia 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                9/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>